Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333398 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,359
- Enrollment target
NCT00333398: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00333398 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,359 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00333398, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,359 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effectiveness, safety, and tolerability of an influenza vaccine. Influenza is a highly infectious disease that occurs throughout the world in the winter months. Infection with an influenza virus is a major public health threat as it has the ability to spread rapidly and affect large numbers of people. Up to 1359 healthy adults ages 18 to less than 65 years old will participate in this study for up to 24 days. Volunteers will receive an injection of either influenza vaccine with thimerosal, vaccine without thimerosal, or placebo with thimerosal. Volunteers will be asked to document information about any health changes for 21 days following vaccination. Volunteers will return to the clinic on days 5 and 21 after vaccination to share this information with study staff. On day 21, volunteers will have a physical examination. Blood samples will be taken prior to vaccination and at Day 21 post-vaccination.
Interventions
- BIOLOGICAL CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free
- BIOLOGICAL CSL Trivalent Inactivated Influenza Vaccine with Thimerosal
- BIOLOGICAL Placebo with Thimerosal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,359 participants |
| Start Date | 2006-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00333398 record still lists
NCT00333398 is an interventional study that assigns participants to a tested intervention. Its 1,359 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher).
The record links to 0 conditions, and to 3 interventions - of which CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free is the first listed.
NCT00333398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00333398 about?
NCT00333398 is a clinical study titled "Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults". The purpose of this study is to investigate the effectiveness, safety, and tolerability of an influenza vaccine. Influenza is a highly infectious disease that occurs throughout the world in the winter months. Infection with an influenza virus is a major public health threat as it has the ability to ...
What is the current status of trial NCT00333398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,359 participants. The study started on 2006-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00333398?
The interventions under investigation include: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free (BIOLOGICAL), CSL Trivalent Inactivated Influenza Vaccine with Thimerosal (BIOLOGICAL), Placebo with Thimerosal (BIOLOGICAL).
Who is sponsoring clinical trial NCT00333398?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00333398's enrollment target sits among peer trials
1,359 180th of 2000 higher than 1,821 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia